Banking Recap

Notes Offering Announced for $250.0M

This is a convertible notes exchange and refinancing transaction in the debt capital markets (dcm) product group, involving The Beauty Health Company (referred to in the source material as BeautyHealth) as issuer. The facts block does not specify a sector classification for this record. The disclosed transaction value is $250,000,000.

May 21, 2025·SEC EDGAR (8-K)·pending regulatory·convertible notes exchange / refinancing

Deal value

The facts are sourced from an 8-K filed with the SEC via EDGAR, published on May 21, 2025. The deal's current status is pending regulatory review.

Only one financial advisor is identified in the facts block: Goldman Sachs, which served as the lead and exclusive financial advisor to BeautyHealth, the issuer. The source sentence states: "Goldman Sachs is acting as exclusive financial advisor and Latham & Watkins LLP served as transaction counsel to BeautyHealth."

One legal advisor is identified: Latham & Watkins LLP served as transaction counsel to BeautyHealth, the issuer, per the same source sentence referenced above.

Beyond the classification of this transaction as a convertible notes exchange and refinancing with a disclosed value of $250,000,000, no further detail on the notes' coupon, maturity, conversion price, or other specific terms is included in the facts provided.

Several items are not disclosed in this record: the coupon rate, maturity date, and conversion terms of the convertible notes are not specified, and no expected closing date is given beyond the pending-regulatory status.